Feed / GRAL

GRAIL, Inc.

GRAL

Healthcare · 77.51 -0.1% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

GRAIL, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.

Company-0.1% todayVolume comparison unavailable
Market group0 of 15 activeAerospace & Industrial Services · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • GRAL's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if GRAL's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Diagnostics & Research

No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • GRAL's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods4
Price observations319
Usable filing statements164
Verified relationships12
Evidence supporting the case
  • Latest annual revenue changed +17.2% year over year.
  • Operating margin changed +1361.1 percentage points in the latest annual period.
  • Net margin changed +1336.5 percentage points in the latest annual period.
Evidence challenging the case
  • Diluted shares increased 15.2% in the latest annual period.
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
  • Restructuring and cost reductions has repeated adverse evidence across 3 filings.
Questions before a position
  • EV/sales is 347% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

77.51
6m+45.6%12m+130.5%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2023-01-01$55.5M$-173.89
2023-12-31$93.1M+67.6%$-47.21+0.0%
2024-12-31$125.6M+34.9%$-63.54+2.7%
2025-12-31$147.2M+17.2%$-11.11+15.2%

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dnegative · 4 filings
Cost of Revenue—Amortization of Intangible Assets As a result of the application of pushdown accounting, intangible assets recognized in our standalone financial statements relate to our own technology, and consist of developed technologies and in-process res…
10-Q · May 7, 2026
Legal and regulatory exposurenegative · 3 filings
Legal and professional services expenses decreased $28.6 million primarily due to no longer incurring legal and professional service fees related to compliance with the European Commission hold separate order and transaction costs related to our Spin-Off, com…
10-K · Mar 12, 2026
Restructuring and cost reductionsnegative · 3 filings
141 Table of Contents Goodwill and Intangible Assets Impairment Year Ended Change (in thousands) December 31, 2025 December 31, 2024 $ % Goodwill and intangible assets impairment $ 28,000 $ 1,420,936 $ (1,392,936) (98 %) Goodwill and intangible impairment dec…
10-K · Mar 12, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 19.4× · EV/sales 17.7×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

77.51-0.1% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for GRAL. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for GRAL. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind GRAL

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ILMNIllumina, Inc.supplierMay 7, 2026

For example, Illumina, Inc.

TWSTTwist Bioscience CorporationsupplierMar 12, 2026

We rely on Illumina as a sole supplier for our next-generation sequencers and associated reagents, Madison Industries (“Madison”) as a sole supplier of blood collection tubes, and Twist Bioscience Corporation (“Twist”) as a sole supplier of DNA panels.

Depended on by

BLLNBillionToOne, Inc.competitorMar 11, 2026

As we expand our oncology offerings into applications such as MRD testing, as well as potentially testing for early detection in the future, we anticipate facing competition from a broader universe of companies, including Exact Sciences, Grail, Haystack, whic…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

GRAL is currently a Follower in the organic co-movement group Aerospace & Industrial Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for GRAL; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.